Sage Journals: Discover world-class research

Abstract

BACKGROUND:

Matrix metalloproteinase-9 (MMP-9) is an important mediator of invasion and metastasis in neoplasia. In thyroid cancer expression levels correlate with aggressiveness but data on peripheral MMP-9 levels are less definitive.

OBJECTIVE:

Prospective study evaluating serum MMP-9 in the diagnosis and prognosis of papillary thyroid cancer.

METHODS:

Serum samples of MMP-9 were drawn before surgery in 185 consecutively enrolled patients with nodular thyroid disease, stratified on pathology as benign disease ( $N=$ 88) and papillary thyroid cancer ( $N=$ 97). Serum MMP-9 was measured by an immunometric assay.

RESULTS:

MMP-9 levels were not different between benign vs malignant pathology ( $p=$ 0.3). In papillary thyroid cancer there was no significant difference in MMP-9 levels between histologies, TNM stage and invasive/non-invasive cancers. High-risk patients with multiple features of aggressiveness had significantly higher MMP-9 levels compared to low-intermediate risk patients (767.5 $\pm$ 269.2 ng/ml vs 563.7 $\pm$ 228.4 ng/ml, $p=$ 0.019). A cut-off of 806 ng/ml distinguished high from low-intermediate risk patients with a sensitivity of 60% and a specificity of 87.36%, $p=$ 0.018. In patients with available follow-up data ( $N=$ 78), MMP-9 was higher in patients who required $\geqslant$ 2 doses of ${}^{131}$ I therapy ( $p=$ 0.009) and in those with biochemical evidence of persistent disease/who required additional therapy to achieve disease-free status ( $p=$ 0.017).

CONCLUSION:

Serum MMP-9 is not useful in the diagnosis of PTC, but preliminary data shows that high pre-surgical serum MMP-9 levels may identify patients at higher risk of persistent disease who require intensive treatment. Large volume prospective studies are required to confirm this observation.

Keywords

Matrix metalloproteinase-9 MMP-9 papillary thyroid cancer prognostic marker neoplasia marker

1. Introduction

Thyroid cancer is the most frequent endocrine neoplasia and it’s incidence has risen dramatically in the last 40 years [1, 2]. In patients diagnosed with differentiated thyroid cancer (DTC), the prognosis is usually good, due mostly to the efficacy of radioiodine therapy. A subset of patients can have a more aggressive clinical course, become radioiodine resistant and head toward a fatal outcome. Early identification of this subset of patients would be useful to better guide management: the extent of surgery, the dose of radioiodine and the degree of TSH supression.

In this context, cancer research was focused on attempting to identify an easily measured serum molecule, to serve as a diagnostic and prognostic marker of neoplasia. One such marker, which has attracted a lot of interest in the past years, is Matrix metalloproteinase-9 (MMP-9) [3].

Matrix metalloproteinases (MMPs) are zinc- dependent endoproteinases whose enzymatic activity is primarily directed against components of the basement membrane and extracellular matrix (ECM). MMP-9 is physiologically expressed mainly in immune cells but also in fibroblasts and endothelium cells, and its expression can be induced or repressed by adhesion molecules, growth factors, cytokines and hormones that act through various signalling pathways to control transcription of the MMP-9 gene [3]; MMP-9 is overexpressed in almost all human cancers, and its expression is further augmented by the cross-talk signalling between the surrounding stroma and the inflamatory cells in the tumor microenvironment [3, 4]. It is believed that tumor cells use the MMP-9 in the tumor microenvironment for invasion and metastasis; MMP-9 further stimulates the release of VEGF (vascular endothelial growth factor) contributing to angiogenesis [3, 4].

In thyroid nodular disease, high MMP-9 expression was found to be able to distinguish malignant from benign tumors [5, 6]; in differentiated thyroid cancer, high expression of MMP-9 was associated with lymph node metastasis, invasion and generally higher tumor stages [5, 6, 7, 8]. Furthermore, mutational analysis suggested that MMP-9 might be one of the mediators of tumor invasiveness in BRAF ${}^{\text{V600E}}$ positive PTCs [9]. IHC expression of MMP-9 was significantly associated with the presence of BRAF ${}^{\text{V600E}}$ mutation in a subgroup of patients with classical PTC [10], although this was not always observed [5] which suggests that other transcription factors are likely to be involved in MMP gene regulation.

It is expected that changes in the tumor microenvironment will be reflected in the body fluids and, considering the relative ease of measurement in blood samples with immunometric assays, MMP-9 could be an ideal marker for helping with cancer diagnosis and prognosis. Indeed, studies have detected abnormal peripheral blood levels of MMP-9 in a variety of neoplasias, with high levels generally related to poor outcomes [4, 11, 12, 13, 14, 15, 16, 17]. There are few studies on MMP-9 levels in the blood of patients with thyroid cancer, and they are all limited by the small numbers of patients [18, 19, 20, 21].

In this context we aimed to assess serum levels of MMP-9 in benign and malignant thyroid disease of the follicular epithelium and i) evaluate its role as a diagnostic and prognostic marker in thyroid neoplasia and ii) evaluate its relationship with clinical and pathological features of aggressiveness of thyroid cancer associated with a worse prognosis.

2. Patients and methods

We assessed serum MMP-9 in 185 consecutively enrolled patients with nodular thyroid disease who underwent thyroid surgery between December 2012 and November 2016 at the “CI Parhon” National Institute of Endocrinology. Patients were informed about the study procedures and gave their written informed consent. The study was performed in strict agreement with the Helsinki declaration concerning ethical principles for medical research involving human subjects. The institutional ethics committee revised and agreed the study protocol.

Patients were divided into 2 groups, according to the pathology report: benign disease (BD) ( $N=$ 88) and papillary thyroid carcinoma (PTC) ( $N=$ 97). Patients diagnosed before surgery with medullary thyroid carcinoma after FNAB and calcitonin measurement were excluded, and no cases of anaplastic thyroid carcinoma, lymphoma or thyroid metastases were identified on pathology.

For patients with PTC, the pathology report included the histological subtype, the presence or absence of multifocality and invasion, size of primary nodule and pathology pT stage.

The histology subtypes of PTC were grouped into: classic PTC (CLS), follicular variant (FV), oxyphil variant of PTC (OXY) and other aggressive forms (AGR), including poorly differentiated, tall cell, insular, solid and sclerosing subtypes. The presence of capsular invasion and gross extra-thyroidal invasion was evaluated based on pathology and imaging data, and patients were grouped into “No invasion”, “Microscopic invasion” and “Macroscopic invasion” groups. Lymphovascular invasion, thought to be a risk factor for adverse prognosis of PTC, was also evaluated and used as a criterion of recurrence risk assessment.

In terms of pTNM staging, according to the AJCC 7th Edition/TNM Classification System for Differentiated Thyroid Carcinoma [22], patients were classified as pT1, pT2, pT3 and pT4 stage. Cross-sectional imaging data and radioiodine scans were used to assess the presence of metastasis and establish the TNM stage.

Imaging evaluation performed before surgery (when indicated), pathological features, as well as information collected after surgery: ultrasound, stimulated thyroglobulin, radioiodine scans, were used to classify patients according to the 2015 American Thyroid Association risk stratification, into Low risk, Intermediate risk and High risk of reccurence [23].

Sera was collected in all patients 1–2 days before surgery. As inflammation after biopsy may influence serum MMP-9 levels, in those patients in which FNAB was performed serum samples were collected after more than one month after FNAB.

Blood samples were collected in serum tubes with clot activator (Kabevette ${}^{\@setsize{\scriptsize}{8pt}{\viipt}{\@viipt}\textregistered}$ Serum (Z)/Gel tubes). Samples were allowed to clot at room temperature and centrifuged immediately after clot formation. After serum was separated, aliquots were stored at $-$ 80 ${}^{\circ}$ until MMP-9 analysis was performed.

MMP-9 was measured by a specific immunometric assay supplied by R&D Systems (Quantikine human MMP-9 (total)). The assay uses the quantitative sandwich enzyme immunoassay technique and recognizes pro-MMPs, active MMPs and to different extents MMP/TIMP complexes [24].

After surgery thyroid cancer patients were prospectively followed-up in the Institute and radioiodine therapy was performed when indicated after risk assessment stratification. Clinical, biochemical and imaging data were collected after each visit and at the end of follow-up in order to evaluate the response to treatment, according to the recommended dynamic risk stratification system [23]. Complete follow-up data was available in 78 patients who were included in the analysis. At the end of follow-up, patients were classified as having no evidence of disease (NED) if they had a stimulated thyroglobulin of $<$ 1 ng/ml after radioiodine ablation (or $<$ 2 ng/ml in the absence of radioiodine ablation), normal thyroglobulin antibodies and negative imaging (neck ultrasound, radioiodine scan and/or cross-sectional imaging when indicated). Biochemical evidence of persistent disease (BED) was defined as a stimulated thyroglobulin of $\geqslant$ 1 ng/ml after radioiodine ablation (or $\geqslant$ 2 ng/ml in the absence of radioiodine ablation) or abnormal thyroglobulin antibodies levels and negative imaging. No patients were identified to have structural/functional evidence of disease at the end of follow-up and no recurrences were identified – i.e. new biochemical, structural or functional evidence of disease after a period of NED.

3. Statistical analysis

Statistical analysis was performed with Medcalc software version 14.8.1. Normal distribution of all groups was evaluated with the Kolmogorov-Smirnov test; independent $t$ -test was performed for comparison between groups if normal distribution was confirmed; if results were not normally distributed, even after logarithmation, a Mann-Whitney test was performed instead. For multiple group comparison, we performed an ANOVA test with post-hoc analysis if normal distribution was previously confirmed and a Kruskall Wallis test if not. The association between categorical variables was tested with the chi square test. Results are expressed as means $\pm$ SD for normally distributed data and as median and data range (minimum, maximum) or interquartile range (25th, 75th percentile) for non-normally distributed data. Strength of linear correlation for normally distributed data was evaluated with Pearson correlation coefficient. The receiver operating characteristic (ROC) curve was plotted and the area under the curve (AUC), sensitivity and specificity were calculated in order to evaluate the adequacy of MMP-9 serum level as a diagnostic and prognostic marker. P less than 0.05 was considered significant.

4. Results

The demographical data of all patients and a summary of MMP-9 levels in patients with papillary thyroid cancer and benign nodular disease are presented in Table 1. Both cancer patients and patients with benign goiters were predominantly female (77.3% vs 82.9%), with no significant difference in gender balance between groups ( $p=$ 0.439). There was no difference in age between patients with benign disease and PTC (49.4 $\pm$ 12.54 years vs 48.2 $\pm$ 14.7 years, $p=$ 0.567), either in women or in men. In patients with benign disease, women were younger than men (47.8 $\pm$ 12.3 years vs 57.1 $\pm$ 10.8 years, $p=$ 0.008), probably reflecting a higher addressability to the endocrinologist, but no difference in age was noted in female vs male cancer patients.

Table 1
Demographical data of patients, average MMP-9 levels

	BD	PTC	$P$
No. (%)	88/185 (47.6%)	97/185 (52.4%)
Sex
Women	73 (82.9%)	75 (77.3%)	0.439 ${}^{\#}$
Men	15 (17.1%)	22 (22.7%)
Age (total)	49.4 $\pm$ 12.54	48.2 $\pm$ 14.7	0.567 ${}^{\#}$
Women	47.8 $\pm$ 12.3 ${}^{*}$	48 $\pm$ 13.9 ${}^{**}$	0.909 ${}^{\#}$
Men	57.1 $\pm$ 10.8 ${}^{*}$	48.9 $\pm$ 17.5 ${}^{**}$	0.113 ${}^{\#}$
MMP-9 (ng/ml)	541.6 $\pm$ 199.2	584.6 $\pm$ 239.8	0.300 ${}^{\#}$

BD – Benign disease; PTC – Papillary thyroid carcinoma. ${}^{*}$ Women with benign disease significantly younger than men ( $p=$ 0.008); ${}^{**}$ no difference in age between gender groups in cancer patients ( $p=$ 0.816). ${}^{\#}$ Independent sample $t$ -test, $p<$ 0.05 considered significant.

Figure 1.

A. Box and whisker plot of MMP-9 values for benign vs malignant disease ( $p=$ 0.3). B. ROC curve of MMP-9 showing lack of discrimination between benign and malignant disease, AUC of 0.545, ( $p=$ 0.288).

There was no difference in MMP-9 levels between patients with benign vs malignant pathology when evaluated as a group (541.6 $\pm$ 199.2 ng/ml vs 584.6 $\pm$ 239.8 ng/ml, $p=$ 0.3) and ROC curve analysis confirmed that serum MMP-9 cannot discriminate between benign or malignant disease, AUC $=$ 0.545 (0.470–0.618), $p=$ 0.288 (cut-off criterion 413 ng/ml, sensitivity 79.4%, specficity 31.8%) – Fig. 1.

MMP-9 levels tended to be lower in older patients when all samples were considered (Pearson $r=$ $-$ 0.158, $p=$ 0.03), although the correlation was very weak and thus not clinically significant; no correlation was noted between MMP-9 levels and age in either patients with benign disease ( $r=$ $-$ 0.159, $p=$ 0.14) or cancer patients ( $r=$ $-$ 0.134, $p=$ 0.19).

The clinical and pathological characteristics of patients with PTC are presented in Table 2.

Table 2

Clinical and pathological characteristics of PTC patients

	No. (%)	MMP-9 (ng/ml)	$P$
Age
$<$ 45 years	38 (39.2%)	623.7 $\pm$ 228.4	0.106 ${}^{\#}$
$\geqslant$ 45 years	59 (60.8%)	559.6 $\pm$ 245.7
Histology
CLS	36 (37.1%)	595.3 $\pm$ 268.4	0.887 ${}^{\$}$
FV	43 (44.3%)	587.1 $\pm$ 226.7
OXY	5 (5.15%)	612.6 $\pm$ 92.8
AGR	13 (13.4%)	537.1 $\pm$ 253.8
Multifocality
MFoc	38 (39.2%)	633.1 $\pm$ 295	0.306 ${}^{\#}$
Ufoc	59 (60.8%)	553.6 $\pm$ 192.9
ETE
No	65 (67%)	592.4 $\pm$ 233.5	0.116 ${}^{\$}$
Micro	24 (24.7%)	524 $\pm$ 242.7
Macro	8 (8.2%)	705.1 $\pm$ 260.1
pT stage
pT1	39 (40.2%)	586.3 $\pm$ 235.7	0.950 ${}^{\$}$
pT2	19 (19.6%)	587.2 $\pm$ 261.4
pT3	36 (37.1%)	579.4 $\pm$ 245
pT4	3 (3.09%)	–
Tumor size
$<$ 1 cm	42 (43.3%)	578.1 $\pm$ 235.3	0.879 ${}^{\$}$
1–2 cm	21 (21.6%)	568.3 $\pm$ 275.4
2–3 cm	18 (18.6%)	641.8 $\pm$ 298.1
$>$ 3 cm	16 (16.5%)	568.7 $\pm$ 168.5
TNM stage
1	58 (59.8%)	592.3 $\pm$ 221.5	0.573 ${}^{\$}$
2	14 (14.4%)	644 $\pm$ 329.1
3	20 (20.6%)	533.5 $\pm$ 235.8
4	5 (5.2%)	536.6 $\pm$ 191
ATA risk
HR	10 (10.3%)	767.5 $\pm$ 269.2	0.019 ${}^{\#}$
L-IR	87 (89.7%)	563.7 $\pm$ 228.4

CLS – classic PTC; FV – follicular variant PTC; AGR – aggressive histology; MFoc – multifocal; UFoc – unifocal; ETE – extrathyroidal extension; No – no invasion; Micro – microscopic invasion; Macro – macroscopic invasion; LR – low risk; IR – intermediate risk; HR – high risk. ${}^{\#}$ Independent sample $t$ -test, ${}^{\$}$ ANOVA with post-hoc analysis, $p<$ 0.05 considered significant.

Figure 2.

A. Box and whisker plot of MMP-9 values showing that patients with High-risk (HR) PTC had significantly higher pre-surgical MMP-9 levels compared to Low-risk – Intermediate-risk (L-IR) patients ( $p=$ 0.019). B. ROC curve analysis revealed that a cut-off value of 806 ng/ml can distinguish high from low-intermediate risk patients with a sensitivity of 60% and a specificity of 87.36%, with an AUC $=$ 0.731 (0.631–0.816), $p=$ 0.018. C. Box and whisker plot of MMP-9 values in PTC patients showing that patients who required $\geqslant$ 2 ${}^{131}$ I doses had significantly higher pre-surgical MMP-9 levels compared to patients in whom radioiodine ablation was not indicated or those in whom no further treatment was required after the initial ${}^{131}$ I dose ( $p=$ 0.009). D. In patients who required ${}^{131}$ I therapy, those who achieved NED status (no evidence of disease) after the initial ${}^{131}$ I dose had significantly lower MMP-9 levels compared to those who required further treatment to achieve NED or those who remained BED (biochemical evidence of disease persistence) at the end of follow up.

MMP-9 levels did not differ significantly between patients younger or older than 45 years old ( $p=$ 0.106). There was also no difference between different histological subtypes ( $p=$ 0.865), different pT stage ( $p=$ 0.950) and TNM stage ( $p=$ 0.573) or between patients with multifocal vs unifocal cancers ( $p=$ 0.306). MMP-9 was also not different in patients with smaller or larger tumors ( $p=$ 0.879) or in patients with or without lymph node metastasis ( $p=$ 0.462), although evaluation of lymph nodes was not routinely performed. The 8 patients with cancers presenting with macroscopic extrathyroid extension (ETE) tended to have higher MMP-9 levels compared to those without extension or with only microscopic ETE, but the difference was not statistically significant ( $p=$ 0.116), possibly due to the small number of patients. Of the 97 patients with PTC, only 3 had distant metastases at diagnosis (all in the lung), too few for a relevant statistic analysis (MMP-9 was 442, 910 and 1124 ng/ml, respectively). On the other hand, high risk patients according to ATA criteria (patients with either extrathyroidal macroscopic invasion or distant metastases) had significantly higher MMP-9 levels compared to low and intermediate risk patients (767.5 $\pm$ 269.2 ng/ml vs 563.7 $\pm$ 228.4 ng/ml, $p=$ 0.019) (Fig. 2A), suggesting that serum MMP-9 can be used as a complementary prognostic factor when measured before surgery. ROC curve analysis revealed that a cut-off value of 806 ng/ml can distinguish high from low-intermediate risk patients with a sensitivity of 60% and a specificity of 87.36%, with an AUC $=$ 0.731 (0.631–0.816), $p=$ 0.018 (Fig. 2B).

Complete data concerning response to treatment and outcomes was available in 78 cancer patients who were followed-up for a median of 58.5 months (range 3–82 months) – Table 3. Of the 78 patients, 53 were low-risk according to the ATA criteria, 20 were intermediate risk and 5 were high-risk papillary thryoid cancer.

Table 3

Response to treatment in PTC patients

	No. (%)	MMP-9 (ng/ml)	$P$
${}^{131}$ I therapy
No ${}^{131}$ I	22 (28.2%)	540 $\pm$ 155.8	0.009 ${}^{\$}$
1 dose ${}^{131}$ I	50 (64.1%)	587.5 $\pm$ 263.9
$\geqslant$ 2 doses ${}^{131}$ I	6 (7.7%)	882 $\pm$ 235.8
Response to treatment
No I ${}^{131}$	22 (28.2%)
NED w/o further Tx	17 (77.3%)	563.1 $\pm$ 147.2	0.208 ${}^{\#}$
BED	5 (22.7%)	461.6 $\pm$ 175.3
I ${}^{131}$	56 (71.8%)
NED w/o further Tx	47 (83.9%)	523 (423 to 690.3)	0.0175 ${}^{\&}$
Further Tx needed	9 (16.1%)	832 (695.8 to 911)
NED with further Tx	3 (5.4%)
BED	6 (10.7%)

I ${}^{131}$ – radioiodine therapy; NED – no evidence of disease; BED – biochemical evidence of persistent disease; w/o – without; Tx – treatment. ${}^{\$}$ ANOVA with post-hoc analysis. ${}^{\#}$ Independent sample $t$ -test. ${}^{\&}$ Mann-Whitney, $p<$ 0.05 considered significant.

In 22 low-risk patients radioiodine ablation was not indicated. At the end of follow-up, of these 22 patients, 18 presented no evidence of disease (NED), while 4 presented with minimally elevated, stable stimulated thyroglobulin levels, median 4.32 ng/ml (range 4.11–5.96 ng/ml) most likely reflecting small thyroid remnants (classified for the purpose of this study as minimal biochemical evidence of disease).

The remaining 56 patients underwent radioiodine therapy, receiving a total median ${}^{131}$ I dose of 50.15 mCi, range 30–619 mCi; 6 patients required $\geqslant$ 2 ${}^{131}$ I doses – Table 3. Patients who required $\geqslant$ 2 ${}^{131}$ I doses had significantly higher MMP-9 levels before surgery compared to those who only received one dose of ${}^{131}$ I or those who did not require ${}^{131}$ I therapy (882 ng/ml vs 587.5 ng/ml vs 540 ng/ml, ANOVA $F=$ 5.028, $p=$ 0.009), suggesting that pre-surgical MMP-9 levels can select patients with more aggresive forms of cancer who will require more intensive treatment (Fig. 2C).

Of the 56 patients who underwent initial radioiodine ablation, 47 patients (83.9%) showed no evidence of disease (NED) at the end of follow-up without further treatment. 3/56 patients (5.4%) achieved NED status after further ${}^{131}$ I treatment, while 6/56 patients (10.8%) presented with biochemical evidence of persistent disease (median stimulated thyroglobulin 5.08 ng/ml (range 2.23–30 ng/ml)). Patients who achieved NED without further treatment after total thyroidectomy and the initial radioiodine ablation (47 patients) had significantly lower serum MMP-9 before surgery compared to those patients who either required further ${}^{131}$ I therapy to achieve NED status or who remained with biochemical evidence of disease at the end of follow-up (9 patients): 523 ng/ml (interquartile range 423 to 690.3) vs 832 (695.8 to 911), Mann Whitney U $=$ 105, $=$ $-$ 2.376, $p=$ 0.0175 (Fig. 2D). This also seems to suggest that higher pre-surgical MMP-9 levels tend to identify patients with more advanced/aggressive PTC.

No patients were identified to have structural/ functional evidence of disease at the end of follow-up. No recurrences were identified (i.e. new biochemical, structural or functional evidence of disease after a period of NED) so the association between MMP-9 levels and the risk of recurrence could not be investigated.

5. Discussion

There is increasing evidence supporting the involvement of MMP-9 in the development and progression of neoplasia, including thyroid cancer. MMP-9 takes part in several dysregulated signalling pathways that lead to tumor cell proliferation and invasion, metastasis, inhibiting apoptosis, contributing to angiogenesis and escaping the immune surveillance [3, 4, 25]. High peripheral MMP-9 levels have been identified in various forms of neoplasia [4, 11, 12, 13, 14, 15, 16, 17]; there are, however, only a few studies concerning thyroid cancer [18, 19, 20, 21], usually with small numbers of patients included.

In our study the original assumption was that patients with thyroid cancer: i) would have higher levels of serum MMP-9 than those with benign nodular goiters; ii) patients with aggressive thyroid cancer would have higher MMP-9 levels compared to milder forms. The published literature on tissue expression of MMP-9 in thyroid cancer seemed to suggest that. High MMP-9 expression was noted in thyroid cancer tissue vs normal thyroid cells and vs benign nodular disease [5, 7, 26, 27, 28]. In PTC higher MMP-9 expression was noted in older PTC patients (age $\geqslant$ 45 years), in patients with lymph node metastasis [5, 6, 8, 27] and/or intra-thyroidal invasion [7] and those with higher tumor stages (III/IV) [5, 6, 27]. High MMP-9 expression was an independent risk factor for predicting persistent/recurrent disease after surgery [6].

Contrary to our expectations, we found no difference in MMP-9 levels between patients with cancer and benign nodules, suggesting that, as opposed to tissue MMP-9 expression, serum MMP-9 would not be useful in the diagnosis of PTC before surgery. Similarly, an early Japanese study by Maruyama et al. identified no difference in serum MMP-9 levels in PTC patients vs control, although tissue levels were significantly higher in PTC compared to benign thyroid disease or controls [21]. In contrast, Zhou et al. identified significantly higher serum levels of MMP-9 in PTC patients vs patients with bening thyroid disease and vs normal controls, as measured by both ELISA and RT-PCR [19]. Lin et al. identified significantly higher plasma VEGF and MMP-9 levels in patients with PTC vs bening thyroid disease and controls, but their levels in early stages of PTC (stage I and II) did not differ from the control or the benign group, suggesting their limited usefulness as diagnostic markers in early PTC [20]. However, in terms of prognosis, VEGF and MMP-9 levels were higher in PTC patients with larger tumors, local invasion, lymph node or distant metastasis [20].

In contrast, in our PTC patients we found no association between the MMP-9 level and tumor size, pT stage, TNM stage, presence or absence of multifocality. There was also no difference in MMP-9 levels between patients with classic PTC, follicular variant, oxyphil variant and other aggressive histologies, although it is worth noting that the “aggressive” group was heterogeneous, including patients with poorly differentiated, solid, sclerosing and oxyphil variants, too few to be evaluated statistically individually.

It is of note that most studies of differentiated thyroid cancer performed so far, whether concerned with tissue expression of MMP-9 [5, 6, 8, 27, 28] or peripheral blood levels [20], associate high MMP-9 levels with lymph node metastases. This is important, since PTC spreads mostly through lymph vessels and recurrences generally occur in the lymph nodes of the neck. In some of these studies, central and/or lateral neck dissection was performed routinely [6, 8]; however, there is evidence that nodal micro-metastases can be present in up to 80% of patients with PTC but adverse prognosis is limited to those patients with macroscopic, clinically evident node involvement [29]. So, although MMP-9 apparently correlates with lymph node metastasis, it is debatable whether this association is indeed relevant to prognosis. In our PTC patients we found no association between MMP-9 level and lymph node metastasis, but lymph nodes were evaluated at pathology in a minority of patients, as current guidelines recommend node dissection as part of PTC surgery only in cases with clinical node involvement [23].

In terms of invasion, it is strongly suggested that it is gross extra-thyroidal extension (based on radiological and clinical data showing a tumor extending beyond the thyroid capsule) that represents a negative prognostic factor, as opposed to microscopic extension, proven at pathology, which has minor significance [30]. Because of this, the 2018 update of the TNM staging system removed the presence of microscopic extrathyroid extension from the criteria for pT3 stage [31]. Our patients with macroscopical extra-thyroidal extension tended to have slightly higher MMP-9 levels, however the difference was not statistically significant.

According to the ATA risk stratification system, patients with macroscopical tumor invasion and incomplete resection are considered at high risk of recurrence. Other high-risk features are the presence of metastatic lymph nodes $>$ 3 cm in size, distant metastases and high thyroglobulin levels suggesting distant metastases [23]. Looking at all these high-risk patients, we found that they had significantly higher MMP-9 compared to Low-Intermediate risk patients. A cut-off value of 806 ng/ml for serum MMP-9 measured before surgery can distinguish high from low-intermediate risk patients with a sensitivity of 60% and a specificity of 87.36%, potentially providing a useful tool in the pre-op evaluation of a patient with thyroid cancer. It means that we could, potentially, identify high risk patients before surgery and use this information to better guide management: plan additional imaging, determine the extent of surgery and the dose of radioiodine to be administered.

In fact, looking at the response to treatment and final outcomes of our patients, we found that MMP-9 levels were significantly higher in patients who required repeated doses of ${}^{131}$ I therapy and in those who showed biochemical evidence of persistent disease at the end of follow-up or who required additional therapy to achieve disease-free status ( $p=$ 0.017). This suggests that pre-surgical MMP-9 levels could, indeed, be used to select patients with more aggressive cancer who will require intensive treatment. No recurrences were identified, reflecting the overall good prognosis of differentiated thyroid cancer (as we pre-operatively recruited consecutive, unselected patients) so the association between MMP-9 levels and the risk of recurrence could not be investigated. Large volume prospective studies would be required to adequately assess this aspect.

In interpreting our results several observations should be made. We expected to find higher serum MMP-9 levels in cancer patients vs benign disease and we also expected more clear correlations between MMP-9 levels and pathological features of aggressiveness in PTC patients. It is worth noting, however, that the strongest evidence of the connection between MMP-9 and PTC aggressiveness comes from histological studies of MMP-9 expression; serum or plasma measurements of MMP-9 seem to provide less clear, sometimes contradictory results. It is quite likely that blood levels of MMP-9 (and probably MMPs in general) only partially reflect the events occuring in the tumor microenvironment. Some of the causes relate to biological factors, such as secretion from the tumor into the bloodstream and MMP-9 leakage from blood cells, and some are related to artefacts from the measurement assay.

Moreover, when evaluating blood levels of MMPs, the existence of different sources of secretion must be taken into account. Increased levels of MMP-9 have been identified in a variety of disease processes, including vascular, inflammatory, degenerative and autoimmune disorders, apart from neoplasia, which lowers the MMP-9 specificity for cancer [3]. This could be particularly important in the evaluation of thyroid nodular disease, considering the high prevalence of autoimmune thyroiditis which is characterized by episodes of inflammation and tissue remodelling.

Another general limitation of studies on peripheral MMP-9 levels relates to the measurement assay. If measured by ELISA, MMP-9 levels reflect immunoreactivity in the biological sample being studied, which may include proMMP-9, activation forms (representing 1–2% of pro-MMPs), degradation products, monomers, oligomers, heterocomplexes and even non-covalent complexes with TIMP-1 [3, 24]. These different MMP-9 forms have distinct and overlapping biological activites in normal physiological conditions as well as cancer. This is an important aspect when comparing results from different studies, because different ELISA assays can detect different active forms/complexes of MMPs.

Finally, the method of collection and storage as part of the pre-analytical stage of MMP determination is essential [24]. There is ample evidence that the type of sample used for the determination, serum or plasma, can provide significantly different results, generally with higher MMP levels in serum vs plasma [32]. This is particularly true for MMP-9 and TIMP-1 due to variable release from platelets, as these contain high levels of MMP-9 and TIMP-1 [13, 32, 33]. The presence of coagulation accelerators in serum samples or anticoagulants in plasma samples further influence the results, mainly as the consequence of the MMP secretion/release in the coagulation/fibrinolisys pathways [13, 34]. Several authors noted that proMMP-9 and active MMP-9 levels in serum and plasma are only weakly correlated [33] or not correlated [35], which led them to call into question the validity of measuring MMP-9 in serum samples. On the other hand, it has been proved that serum and plasma total MMP-9 levels are significantly correlated in both healthy controls and diseases characterized by high MMP-9 levels, so MMP-9 can be regarded as a valid biomarker even when measured in serum samples [17, 35, 36]. In fact, there are several studies that have identified a positive diagnostic and prognostic role of high MMP-9 measured in the serum in different neoplasias. In colorectal cancer a significant association was found between high serum MMP-9 and neoplasia [15, 16], although a later larger scale study failed to confirm this association [37]. In patients with breast disease, higher serum MMP-9 levels could distinguish breast cancer from benign disease; MMP-9 was associated with more advanced disease, lymph node involvement and metastatic presentation [11, 14]. In contrast, in patients with gastric cancer, only plasma and not serum MMP-9, was able to distinguish cancer patients from controls and correlated significantly with lymph node metastasis, venous invasion and poor survival [17].

In the end, although its role in cancer development seems certain, whether it is in serum or plasma samples, and whether active MMP-9, proMMP-9 or total MMP-9 is better in terms of diagnostic and prognostic value is still to be determined.

6. Conclusion

There is a wealth of evidence suggesting that MMP-9 is an important mediator of cancer growth, invasion and metastasis. In thyroid cancer there are few studies of peripheral levels of MMP-9 and these are small and show conflicting results. Ours is the first large-scale study to investigate the role of MMP-9 as a circulating marker in differentiated thyroid cancer.

Our data suggest that serum MMP-9 is not a useful diagnostic marker for papillary thyroid carcinoma, as MMP-9 levels were not different in patients with benign nodular disease and papillary thyroid cancer. However, we found higher MMP-9 levels pre-operatively in patients with high risk papillary thyroid carcinoma, in those who required repeated doses of ${}^{131}$ I therapy and in those who showed biochemical evidence of persistent disease at the end of follow-up or who required additional therapy to achieve disease-free status. This indicates that pre-surgical serum MMP-9 levels might be used as a complementary prognostic marker, selecting patients with aggressive papillary thyroid carcinoma who will require more intensive treatment and more careful follow-up.

Footnotes

Acknowledgments

This study was supported by UEFISCDI grant PN-II-PT-PCCA-2011-3.2 no.135/2012.

Conflict of interest

No competing financial interests exist.

References

Davies

and Welch

H.G.

, Current thyroid cancer trends in the United States, JAMA Otolaryngol Head Neck Surg 140 (2014), 317–322.

Wiltshire

J.J.

Drake

T.M.

Uttley

and Balasubramanian

S.P.

, Systematic review of trends in the incidence rates of thyroid cancer, Thyroid 26 (2016), 1541–1552.

Vandooren

Van den Steen

P.E.

and Opdenakker

, Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade, Crit Rev Biochem Mol Biol 48 (2013), 222–272.

Sbardella

Fasciglione

G.F.

Gioia

Ciaccio

Tundo

G.R.

Marini

and Coletta

, Human matrix metalloproteinases: An ubiquitarian class of enzymes involved in several pathological processes, Mol Aspects Med 33 (2012), 119–208.

Zarkesh

Zadeh-Vakili

Akbarzadeh

Fanaei

S.A.

Hedayati

and Azizi

, The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer, BMC Cancer 18 (2018), 1199.

Liu

Zhou

Yan

Chen

Zhang

and Hu

, Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis, Oncol Lett 17 (2019), 2308–2316.

Maeta

Ohgi

and Terada

, Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas, Virchows Arch 438 (2001), 121–128.

Zhang

Luo

Y.K.

Zhang

M.B.

C.T.

Tang

and Li

J.L.

, Values of ultrasound features and MMP-9 of papillary thyroid carcinoma in predicting cervical lymph node metastases, Sci Rep 7 (2017), 6670.

Mesa

, Jr. Mirza

Mitsutake

Sartor

Medvedovic

Tomlinson

Knauf

J.A.

Weber

G.F.

and Fagin

J.A.

, Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling, Cancer Res 66 (2006), 6521–6529.

10.

Frasca

Nucera

Pellegriti

Gangemi

Attard

Stella

Loda

Vella

Giordano

Trimarchi

Mazzon

Belfiore

and Vigneri

, BRAF(V600E) mutation and the biology of papillary thyroid cancer, Endocr Relat Cancer 15 (2008), 191–205.

11.

Patel

Sumitra

Koner

B.C.

and Saxena

, Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression, Clin Biochem 44 (2011), 869–872.

12.

Turpeenniemi-Hujanen

, Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers, Biochimie 87 (2005), 287–297.

13.

Jung

Lein

Laube

and Lichtinghagen

, Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood, Clin Chim Acta 314 (2001), 241–244.

14.

Provatopoulou

Gounaris

Kalogera

Zagouri

Flessas

Goussetis

Nonni

Papassotiriou

and Zografos

, Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease, BMC Cancer 9 (2009), 390.

15.

Wilson

Damery

Stocken

D.D.

Dowswell

Holder

Ward

S.T.

Redman

Wakelam

M.J.

James

Hobbs

F.D.

and Ismail

, Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test, Br J Cancer 106 (2012), 1431–1438.

16.

Hurst

N.G.

Stocken

D.D.

Wilson

Keh

Wakelam

M.J.

and Ismail

, Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients, Br J Cancer 97 (2007), 971–977.

17.

C.Y.

M.S.

Chiang

E.P.

Chen

Y.J.

Chen

C.J.

Chi

N.H.

Shih

Y.T.

Chen

G.H.

and Lin

J.T.

, Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution, Clin Cancer Res 13 (2007), 2054–2060.

18.

Komorowski

Pasieka

Jankiewicz-Wika

and Stepien

, Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer, Thyroid 12 (2002), 655–662.

19.

Zhou

S.F.

S.Y.

Miao

and Mao

W.Z.

, Correlations between papillary thyroid cancer and peripheral blood levels of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2, Chin Med J (Engl) 126 (2013), 1925–1929.

20.

Lin

S.Y.

Wang

Y.Y.

and Sheu

W.H.

, Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer, Clin Endocrinol (Oxf) 58 (2003), 513–518.

21.

Maruyama

Kawata

Shimada

Shinomiya

Hirata

Yamamichi

and Murakami

, Study of matrix metalloproteinase-2 and -9 in thyroid papillary cancer, Nihon Jibiinkoka Gakkai Kaiho 103 (2000), 499–505.

22.

Edge

S.B.

Compton

C.C.

Fritz

A.G.

Greene

F.L.

and Trotti

, Thyroid cancer staging, in: AJCC Cancer Staging Manual Edge

S.B.

Compton

C.C.

Fritz

A.G.

Greene

F.L.

Trotti

, eds., Springer-Verlag, New York, 2010, pp. 59–64.

23.

Haugen

B.R.

Alexander

E.K.

Bible

K.C.

Doherty

G.M.

Mandel

S.J.

Nikiforov

Y.E.

Pacini

Randolph

G.W.

Sawka

A.M.

Schlumberger

Schuff

K.G.

Sherman

S.I.

Sosa

J.A.

Steward

D.L.

Tuttle

R.M.

and Wartofsky

, 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer, Thyroid 26 (2016), 1–133.

24.

Colotti

Angeli

Del Ry

Maltinti

Vittorini

and Giannessi

, Matrix metalloprotease-2 and -9 concentration and activity in serum and culture medium samples: A methodological reappraisal, Clin Chem Lab Med 45 (2007), 1292–1298.

25.

Egeblad

and Werb

, New functions for the matrix metalloproteinases in cancer progression, Nat Rev Cancer 2 (2002), 161–174.

26.

Campo

Merino

M.J.

Liotta

Neumann

and Stetler-Stevenson

, Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue, Hum Pathol 23 (1992), 1395–1401.

27.

Selemetjev

Doric

Paunovic

Tatic

and Cvejic

, Coexpressed high levels of VEGF-C and active MMP-9 are associated with lymphatic spreading and local invasiveness of papillary thyroid carcinoma, Am J Clin Pathol (2016).

28.

Marecko

Cvejic

Selemetjev

Paskas

Tatic

Paunovic

and Savin

, Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration, Croat Med J 55 (2014), 128–137.

29.

Randolph

G.W.

Duh

Q.Y.

Heller

K.S.

LiVolsi

V.A.

Mandel

S.J.

Steward

D.L.

Tufano

R.P.

Tuttle

R.M.

and S. American Thyroid Association Surgical Affairs Committee’s Taskforce on Thyroid Cancer Nodal, The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension, Thyroid 22 (2012), 1144–1152.

30.

Radowsky

J.S.

Howard

R.S.

Burch

H.B.

and Stojadinovic

, Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome, Thyroid 24 (2014), 241–244.

31.

Tuttle

R.M.

Haugen

and Perrier

N.D.

, Updated american joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth Edition): What changed and why? Thyroid 27 (2017), 751–756.

32.

Jonsson

Hjalmarsson

Falk

and Ivarsson

M.L.

, Levels of matrix metalloproteinases differ in plasma and serum – aspects regarding analysis of biological markers in cancer, Br J Cancer 115 (2016), 703–706.

33.

Paula

Anne

T.M.

and Taina

T.H.

, The sample type usedaffects the levels of gelatinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in circulating blood of healthy controls and breast cancer patients, Biomark Insights 2 (2007), 117–127.

34.

Mannello

and Tonti

G.A.

, Gelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: The coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum, Int J Cancer 121 (2007), 216–218; author reply 219–223.

35.

Gerlach

R.F.

Demacq

Jung

and Tanus-Santos

J.E.

, Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma, Clin Biochem 40 (2007), 119–123.

36.

Gerlach

R.F.

Meschiari

C.A.

Marcaccini

A.M.

Palei

A.C.

Sandrim

V.C.

Cavalli

R.C.

and Tanus-Santos

J.E.

, Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions, Clin Chem Lab Med 47 (2009), 888–891.

37.

Damery

Nichols

Holder

Ward

S.T.

Warmington

Wilson

Wakelam

M.J.

James

and Ismail

, Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer, Br J Cancer 108 (2013), 1149–1156.

Serum Matrix metalloproteinase-9 (MMP-9) can help identify patients with papillary thyroid cancer at high risk of persistent disease: Value and limitations of a potential marker of neoplasia

Abstract

BACKGROUND:

OBJECTIVE:

METHODS:

RESULTS:

CONCLUSION:

Keywords

1. Introduction

2. Patients and methods

3. Statistical analysis

4. Results

Table 1 Demographical data of patients, average MMP-9 levels

6. Conclusion

Footnotes

Acknowledgments

Conflict of interest

References

Table 1
Demographical data of patients, average MMP-9 levels